Company research / TRVI

Trevi Therapeutics, Inc. (TRVI)

Build a valuation ↗↓ Download CSV

CIK 0001563880

Key ratios (year ended 2025-12-31)

-23.3%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 10-Q · 2026-08-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Operating Income	-$49.33M	-$51.52M	-$33.92M	-$29.91M	-$32.48M	-$32.49M	-$26.64M	-$18.41M	—
Net Income	-$42.76M	-$47.91M	-$29.07M	-$29.15M	-$33.94M	-$32.76M	-$26.05M	-$20.55M	—
EPS (Diluted)	$-0.32	$-0.47	$-0.29	$-0.45	$-1.49	—	—	—	—
Total Assets	$193.44M	$110.90M	$89.40M	$123.02M	$38.48M	$47.13M	$60.00M	$10.53M	—
Total Liabilities	$10.20M	$11.26M	$6.86M	$15.56M	$21.40M	$19.85M	—	—	—
Shareholders' Equity	$183.24M	$99.64M	$82.55M	$107.46M	$17.07M	$27.28M	$54.55M	-$109.49M	-$84.43M
Cash & Equivalents	$18.91M	$34.10M	$32.40M	$12.59M	$36.83M	$45.00M	$57.31M	$7.20M	—
Operating Cash Flow	-$42.09M	-$38.26M	-$31.71M	-$28.18M	-$28.95M	-$29.00M	-$23.09M	-$18.29M	—
Capital Expenditures	$12.0K	$35.0K	$137.0K	$159.0K	—	$32.0K	$9.0K	$158.0K	—
Shares Outstanding	128.31M	93.60M	68.28M	59.94M	28.51M	18.55M	17.83M	438.6K	—
Weighted Average Diluted Shares	134.75M	101.97M	99.03M	64.54M	22.84M	—	—	—	—
EPS (Basic)	$-0.32	$-0.47	$-0.29	$-0.45	$-1.49	—	—	—	—